终末期肾病患者恶性肿瘤发病机制探讨

张 统1, 薛 凌宇2
1、山东第一医科大学（山东省医学科学院）研究生院
2、山东第一医科大学第二附属医院肾内科

摘要


终末期肾病（end stage renal disease，ESRD）患者恶性肿瘤发病风险显著高于普通人群，其肿瘤发生是免
疫功能障碍削弱肿瘤免疫监视、慢性微炎症状态激活促癌信号通路、氧化应激加剧细胞损伤、尿毒症毒素蓄积所致
DNA损伤与基因组不稳定、透析相关因素（获得性囊性肾病）及药物（如免疫抑制剂）多因素交织的结果。未来需
深入开展大样本研究，探索ESRD患者不同肾脏替代治疗方式下的风险差异及可干预靶点，为个体化肿瘤防治提供
依据。

关键词


终末期肾病；恶性肿瘤；发病率；危险因素；发病机制

全文:

PDF


参考


[1]Xie X, Li F, Xie L, et al. Meta-analysis of cancer risk

among end stage renal disease undergoing maintenance dialysis

[J]. Open Life Sci, 2023, 18(1): 20220553.

[2]Pan HC, Sun CY, Wu IW, et al. Higher risk of

malignant neoplasms in young adults with end-stage renal disease

receiving haemodialysis: a nationwide population-based study [J].

Nephrology (Carlton), 2019, 24(11): 1165-1171.

[3]Myung J, Choi JH, Yi JH, et al. Cancer incidence

according to the National Health Information Database in Korean

patients with end-stage renal disease receiving hemodialysis [J].Korean J Intern Med, 2020, 35(5): 1210-1219.

[4]Choi HS, Han KD, Oh TR, et al. Smoking and risk

of incident end-stage kidney disease in general population:

a nationwide population-based cohort study from Korea [J].

Sci Rep, 2019, 9(1): 19511.

[5]Kumar R, Matulewicz R, Mari A, et al. Impact of

smoking on urologic cancers: a snapshot of current evidence

[J]. World J Urol, 2023, 41(6): 1473-1479.

[6]Lisowska KA, Pindel M, Pietruczuk K, et al. The

influence of a single hemodialysis procedure on human T

lymphocytes [J]. Sci Rep, 2019, 9(1): 5041.

[7]Gupta J, Mitra N, Kanetsky PA, et al. Association

between albuminuria, kidney function, and inflammatory

biomarker profile in CKD in CRIC [J]. Clin J Am Soc

Nephrol, 2012, 7(12): 1938-1946.

[8]Wang M, Chen S, He X, et al. Targeting inflammation

as cancer therapy [J]. J Hematol Oncol, 2024, 17(1): 13.

[9]Sager RA, Susztak K, Hakimi AA. Inflammationdriven field cancerization in end-stage kidney disease [J].

Cancer Discov, 2026, 16(3): 426-427.

[10]Migita T. Is end-stage renal disease tumor suppressive?

Dispelling the myths [J]. Cancers (Basel), 2024, 16(18): 3135.

[11]Rysz J, Franczyk B, Ławiński J, et al. Oxidative stress

in ESRD patients on dialysis and the risk of cardiovascular

diseases [J]. Antioxidants (Basel), 2020, 9(11): 1079.

[12]Yüzbaşıoğlu Y, Hazar M, Aydın Dilsiz S, et al.

Biomonitoring of oxidative-stress-related genotoxic damage in

patients with end-stage renal disease [J]. Toxics, 2024, 12(1): 69.

[13]Motrenikova M, Boyanov K, Bojinova N, et al.

Stress pathways in chronic kidney disease: linking cortisol,

oxidative stress, and inflammation [J]. Antioxidants (Basel),

2025, 14(10): 1259.

[14]Peng YS, Syu JP, Wang SD, et al. BSA-bounded

p-cresyl sulfate potentiates the malignancy of bladder

carcinoma by triggering cell migration and EMT through

the ROS/Src/FAK signaling pathway [J]. Cell Biol Toxicol,

2020, 36(4): 287-300.

[15]Syed-Ahmed M, Narayanan M. Immune

dysfunction and risk of infection in chronic kidney disease [J].

Adv Chronic Kidney Dis, 2019, 26(1): 8-15.

[16]Xie H, Yang N, Yu C, Lu L. Uremic toxins mediate

kidney diseases: the role of aryl hydrocarbon receptor [J]. Cell

Mol Biol Lett. 2024 Mar 15;29(1):38.

[17]Yüzbaşıoğlu Y, Hazar M, Aydın Dilsiz S, et al.

Biomonitoring of oxidative-stress-related genotoxic damage in

patients with end-stage renal disease [J]. Toxics, 2024, 12(1): 69.

[18]Robinson S, Nag A, Peticca B, et al. Renal Cell

Carcinoma in End-Stage Kidney Disease and the Role of

Transplantation [J]. Cancers (Basel), 2023 Dec 19;16(1):3.

[19]Johnson TA, Maekawa S, Fujita M, et al. Genomic

features of renal cell carcinoma developed during end-stage renal

disease and dialysis. Hum Mol Genet. 2023, 32(2):290-303.

[20]Sager RA, Susztak K, Hakimi AA. Inflammationdriven field cancerization in end-stage kidney disease [J].

Cancer Discov, 2026, 16(3): 426-427.

[21]Dai YN, Yi-Wen Yu E, Zeegers MP, Wesselius A.

The association between dietary inflammatory potential and

urologic cancers: A Meta-analysis. AdvNutr. 2024;15:100124.


Refbacks

  • 当前没有refback。